To include your compound in the COVID-19 Resource Center, submit it here.

Checkpoint match

Genentech, Array combine Chk1 programs to improve chances of success

With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an economic incentive to favor one molecule over the other.

The long-time partners announced a new deal this month to develop a preclinical Chk1 inhibitor from Array and a Phase I compound from Genentech. Although Genentech is responsible for development and commercialization, Array is eligible for the same payouts regardless of which program is advanced.

The terms included $28 million up front to Array, up to $685 million in clinical and commercial milestones, and double-digit royalties.

Genentech's GDC-0425 (RG7602)

Read the full 1103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE